Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.
about
Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjectsThe MET axis as a therapeutic target.Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studiesUse of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor.Molecular imaging of cell-based cancer immunotherapy.The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.Suppression of miR-199a maturation by HuR is crucial for hypoxia-induced glycolytic switch in hepatocellular carcinoma.Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer.Quantitative magnetization transfer MRI of desmoplasia in pancreatic ductal adenocarcinoma xenografts.Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin.Targeted therapy for malignant glioma patients: lessons learned and the road ahead.MET targeted therapy for lung cancer: clinical development and future directionsClinical implications of MET gene copy number in lung cancer.Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.Animal tumor models for PET in drug development.MET overexpression and gene amplification in NSCLC: a clinical perspective.Monitoring of tumor response to cisplatin with simultaneous fluorescence and positron emission tomography: a feasibility study.Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474.18F-FDG microPET imaging detects early transient response to an IGF1R inhibitor in genetically engineered rhabdomyosarcoma models.The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected DogsPreclinical evaluation of a novel c-Met inhibitor in a gastric cancer xenograft model using small animal PET.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.[Dysregulation of HGF/c-Met signal pathway and their targeting drugs in lung cancer].
P2860
Q24600166-15254AD5-1C2B-4691-A74A-AF7CB6263D85Q24609682-9832C734-64DA-47BD-BCE9-A5EC2872CCD2Q26778463-2B51D633-8BC1-4C8C-AF74-2CAE11688DF8Q34633685-C3516688-E06B-494D-8ED4-E8D8DF63B5E7Q34717870-E0F89823-143B-4B3E-A3CA-CD6FAE1AE84CQ35563524-A57996A8-70D5-4ADD-AC30-08DB13BD8584Q36270963-EB72FB1B-0356-4108-8023-F3A1901E36A4Q36411841-CB5D5CCA-BBAF-4D7E-8340-C2189714A021Q36533822-88DE7383-A7FB-4DE7-8068-F607276B04A0Q37276919-28057D17-F947-4AE2-A4F4-34501813F070Q37337346-C0401861-B74E-43B8-AA3D-768F047404B9Q37385991-D8CC47A8-4844-4C37-B6A6-45F096A8851FQ37533648-0065A62B-5B46-4BEC-962A-51F910B8E8EBQ37645240-54DA53DA-E4B7-4FDF-929B-6FB2817394BDQ37690299-D3D30F33-F379-468E-A6CE-6CD42F6F0BC1Q37730020-F18F53D7-506A-4B2A-9FFC-D877D9FC3039Q37924161-0B892ADF-3412-4E8A-BEE9-B056090A82A2Q38956316-0094FB8B-59F0-458C-AA21-759E2C4D7B0EQ39125868-EC4236E0-B4E0-4B75-B200-4E6224666F84Q39373209-EC4B6933-B5A4-43DB-AC35-3F9C486217CDQ39413508-896F9226-5B64-442E-BA45-77956454DC30Q39594896-DD38B568-A792-4962-A024-CC7FB72A7CEBQ41901776-C70D6268-B9D8-45A4-94E7-DB1FA0839080Q47302253-CF8B4126-C431-439F-A246-B67F495D8E3EQ50985091-85D66A33-EE54-436D-BC76-EA27272AAADDQ53232399-B47A28D7-521A-46DE-8FEB-90AF6F484AED
P2860
Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@ast
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@en
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@nl
type
label
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@ast
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@en
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@nl
prefLabel
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@ast
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@en
Preclinical efficacy of the c- ...... d by 18F-FDG small-animal PET.
@nl
P2093
P2860
P1476
Preclinical efficacy of the c- ...... ed by 18F-FDG small-animal PET
@en
P2093
James G Christensen
Jeffrey R Tseng
Joseph H Lee
Mangal Dandekar
Neil R Michaud
Patrick W Vincent
Sanjiv S Gambhir
Shahriar Yaghoubi
Stephen Muir
P2860
P304
P356
10.2967/JNUMED.106.038836
P407
P577
2007-12-12T00:00:00Z